Drug intelligence / Profile preview

Jinma Xing Zhi Ke Pian

Development stage: Unknown
Lead developer: Lanzhou Gufang
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Jinma Xing Zhi Ke Pian is a Traditional Chinese Medicine (TCM) formulation developed by Chengde Yanfeng Pharmaceutical for the treatment of acute tracheobronchitis. It is specifically indicated for patients presenting with the TCM pattern of phlegm-heat obstructing the lung (痰热阻肺证). The drug is designed to alleviate symptoms such as cough and sputum production by clearing heat and resolving phlegm. It is currently being evaluated in a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial in China to confirm its efficacy and safety in adult populations.

Other names: 金麻杏止咳片

Beyond the preview

Go deeper on Jinma Xing Zhi Ke Pian.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jinma Xing Zhi Ke Pian.

Explore the full profile